65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

26 trials found

diseases per page:

Showing 1 to 10 of 26 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03033745 (ClinicalTrials.gov)	February 1, 2017	23/1/2017	Safety and Tolerability of Higher Infusion Parameters of IgPro20(Hizentra) in Subjects With Primary ...	An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameter ...	Primary Immunodeficiency	Drug: IgPro20	CSL Behring	NULL	Completed	2 Years	N/A	All	49	Phase 4	United States;Canada
2	NCT01461018 (ClinicalTrials.gov)	October 2011	24/10/2011	Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20in Subjects ...	A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) Ig ...	Primary Immune Deficiency	Biological: Immune globulin subcutaneous (Human)	CSL Behring	NULL	Completed	N/A	75 Years	Both	22	Phase 3	Japan
3	NCT01458171 (ClinicalTrials.gov)	April 2011	12/10/2011	Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan ...	A Multicenter Follow-up Study of Long-term Safety, Tolerability, and Efficacy of Immune Globulin Sub ...	Primary Immune Deficiency Disorder	Biological: Immune globulin subcutaneous (Human)	CSL Behring	NULL	Completed	N/A	75 Years	All	23	Phase 3	Japan
4	NCT01199705 (ClinicalTrials.gov)	September 2010	8/9/2010	Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)	A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcu ...	Primary Immune Deficiency	Biological: Immune Globulin Subcutaneous (Human) (SCIG)	CSL Behring	NULL	Completed	N/A	75 Years	All	25	Phase 3	Japan
5	EUCTR2008-000830-30-SE (EUCTR)	17/12/2008	03/11/2008	A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutane ...	A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutane ...	PID (primary immunodeficiency) MedDRA version: 9.1;Level: LLT;Classification code 10064859;Term: Pri ...	Product Name: IgPro20 Product Code: IgPro20 INN or Proposed INN: normal human immunoglobulin G	CSL Behring AG	NULL	Not Recruiting			Female: yes Male: yes	36		United Kingdom;Germany;France;Spain;Sweden
6	EUCTR2008-000830-30-GB (EUCTR)	10/12/2008	20/01/2009	Extension study designed to test the long-term safety and effectiveness of Immunoglobulin Subcutaneo ...	A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutane ...	PID (Primary Immune Deficiency) MedDRA version: 13.1;Level: PT;Classification code 10064859;Term: Pr ...	Product Name: Hizentra® Product Code: IgPro20 INN or Proposed INN: Human Normal Immunoglobulin	CSL Behring AG	NULL	Not Recruiting			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;Spain;Poland;Romania;Germany;Switzerland;United Kingdom;Sweden
7	EUCTR2008-000830-30-FR (EUCTR)	24/11/2008	21/10/2008	A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutane ...	A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutane ...	PID (primary immunodeficiency) MedDRA version: 9.1;Level: LLT;Classification code 10064859;Term: Pri ...	Product Name: IgPro20 Product Code: IgPro20 INN or Proposed INN: Human Normal Immunoglobulin	CSL Behring AG	NULL	Not Recruiting			Female: yes Male: yes	36	Phase 3	France;Spain;Germany;United Kingdom;Sweden
8	EUCTR2008-000830-30-ES (EUCTR)	12/11/2008	01/10/2008	A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of ImmuneGlobulin Subcutaneo ...	A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of ImmuneGlobulin Subcutaneo ...	Primary Immunodeficiency (PID)inmunodeficiencia primaria (IDP) MedDRA version: 9.1;Level: LLT;Classi ...	Product Name: IgPro20 Product Code: IgPro20 INN or Proposed INN: Human Normal Immunoglobulin	CSL Behring AG	NULL	Not Recruiting			Female: yes Male: yes	36		United Kingdom;Germany;France;Spain;Sweden
9	EUCTR2006-006745-13-PL (EUCTR)	16/10/2008	11/08/2008	A multicenter study of the efficacy, tolerability, safety, and pharmacokinetics of Immune Globuline ...	A multicenter study of the efficacy, tolerability, safety, and pharmacokinetics of Immune Globuline ...	PID (Primary Immunodeficiency) MedDRA version: 9.1;Level: LLT;Classification code 10064859;Term: Pri ...	Product Name: IgPro20 Other descriptive name: IMMUNOGLOBULIN G	CSL Behring	NULL	Not Recruiting			Female: yes Male: yes	43	Phase 3	France;Spain;Poland;Germany;Italy;United Kingdom;Sweden
10	NCT00751621 (ClinicalTrials.gov)	August 2008	11/9/2008	Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension St ...	A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutane ...	Primary Immunodeficiency (PID)	Biological: IgPro20	CSL Behring	NULL	Completed	2 Years	65 Years	All	40	Phase 3	France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom

First Previous1 2 3Next Last